Cellectis (NASDAQ:CLLS) Issues Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Key Points

• Cellectis reported a quarterly loss of ($0.24) earnings per share, missing analysts' expectations by $0.09, while also showing a negative return on equity of 62.55% and a net margin of 114.82%.
• Despite the earnings miss, Cellectis’ stock increased by 2.4% to $3.02 during trading, with significant trading volume rising above the average.
• Institutional investor UBS AM raised its stake by 228.4%, now holding approximately 8.50% of the company's shares, amid overall institutional ownership of 63.90% in Cellectis.

Cellectis (NASDAQ:CLLS - Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09), Zacks reports. Cellectis had a negative net margin of 100.69% and a negative return on equity of 64.20%. The business had revenue of $18.19 million for the quarter, compared to analysts' expectations of $10.07 million.

Cellectis Price Performance

CLLS stock traded up $0.15 on Wednesday, reaching $2.68. 117,890 shares of the company's stock were exchanged, compared to its average volume of 236,402. The stock has a fifty day moving average of $1.77 and a 200-day moving average of $1.55. Cellectis has a twelve month low of $1.10 and a twelve month high of $3.24. The firm has a market cap of $148.95 million, a PE ratio of -3.27 and a beta of 3.03. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.44.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Wall Street Zen lowered Cellectis from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Barclays dropped their price target on shares of Cellectis from $5.00 to $4.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th.

Institutional Trading of Cellectis

A hedge fund recently raised its stake in Cellectis stock. Acadian Asset Management LLC increased its stake in Cellectis S.A. (NASDAQ:CLLS - Free Report) by 132.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 46,377 shares of the biotechnology company's stock after acquiring an additional 26,461 shares during the quarter. Acadian Asset Management LLC owned approximately 0.08% of Cellectis worth $55,000 at the end of the most recent quarter. Institutional investors and hedge funds own 63.90% of the company's stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.